Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Explore this paper's citation graph
Summary
The results argue that these major immunosuppressive pathways are intrinsically driven by the immune system rather than being orchestrated by cancer cells, and imply that cancer immunotherapy approaches targeting negative regulatory immune checkpoints might be preferentially beneficial for patients with a preexisting T cell–inflamed tumor microenvironment.
- Type
- article
- Published
- 2013-08-28
- Cited by
- 1,660
- References
- 61
- Access
- Open access
- OpenAlex
- https://openalex.org/W2136731993
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8828697
Keywords
Tumor microenvironment, FOXP3, Immune system, Cytotoxic T cell, Immunotherapy
References
- Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine.
- Naturally arising CD25+CD4+ regulatory T cells in tumor immunity.
- Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells.
- Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
- ICAM-1 Contributes to but Is Not Essential for Tumor Antigen Cross-Priming and CD8+ T Cell-Mediated Tumor Rejection In Vivo1
- Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
- Induction of Cytotoxic Granules in Human Memory CD8+ T Cell Subsets Requires Cell Cycle Progression1
- B7-H1 pathway and its role in the evasion of tumor immunity
- T cell clonal anergy.
- Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection1
- Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites
- Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
- Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
- Prevention of allogeneic fetal rejection by tryptophan catabolism.
- Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
- Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation.
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Cited by
- Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
- Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer
- Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
- Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma
- Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer
- Immunoengineering through cancer vaccines – A personalized and multi‐step vaccine approach towards precise cancer immunity
- The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function.
- T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers
- Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
- Myeloid‐derived suppressor cells and tumor: Current knowledge and future perspectives
- Association of Tumor Microenvironment T-Cell Repertoire and Mutational Load With Clinical Outcome After Sequential Checkpoint Blockade in Melanoma
- Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment
- miRNA Regulation of Programmed Cell Death-1 in T Cells: Potential Prognostic and Therapeutic Markers in Melanoma
- Comment on “Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans”
- Genomic Applications in Pathology
- Systemic immune changes associated with adjuvant interferon-&agr;2b-therapy in stage III melanoma patients: failure at the effector phase?
Related papers
- The role of Foxp3 in Treg homeostatic proliferation: Necessary for nTregs, but insufficient for iTregs. (LYM3P.734)
- IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3
- Foxp3 as a marker of tolerance induction versus rejection
- [The reduced pulmonary function is related to the decreased expression of Treg and Foxp3 in adjuvant-induced arthritis rats].
- A temporally dynamic Foxp3 autoregulatory transcriptional circuit controls the effector Treg programme
- Research on the expression of Foxp3 in model of type 1 diabetes mellitus
- Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy.
- Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment.
- Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy